Amgen’s Repatha Shows Long-Term Cardiovascular Benefits in Patients Without Prior Heart Events

Amgen’s Repatha (evolocumab) has demonstrated long-term efficacy in reducing major adverse cardiovascular events (MACE) in patients without a history of heart attack or stroke, according to the VESALIUS-CV trial. The study, which enrolled over 12,000 high-risk patients followed for 4.5 years, met its primary endpoints: time to first occurrence of CHD death, heart attack, or ischemic stroke, and time to first occurrence of these events plus ischemia-driven arterial revascularization. Around 85% of participants remained on high- or moderate-intensity LDL-C-lowering therapy. These results reinforce Repatha’s established safety profile and support its use as a key therapy in comprehensive lipid management. The full trial data will be presented at the American Heart Association Scientific Sessions on 8 November. Repatha, the first PCSK9 inhibitor globally approved in 2015, faces competition from Praluent, Leqvio, and emerging LDL-C-lowering therapies, while the overall dyslipidemia market is projected to reach $15.53 billion by 2032 across major markets.

07-10-2025